A recent Scientific Reports study focussed on evaluating the effect of intravenous (IV) N, N-Dimethyltryptamine (DMT), a psychedelic intervention, on the mental health of healthy volunteers. Study: ...

Canadian biopharma company Algernon Pharmaceuticals Inc. AGNPF’s subsidiary Algernon NeuroScience (AGN Neuro) completed dosing the second cohort of its Phase 1 study on the company’s proprietary IV ...

NEW YORK, July 28, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the start of a Phase 1 ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today announced ...

A London biotech startup announced Wednesday that it had found success in treating major depressive disorder with intravenous DMT in a clinical trial. Though follow-up trials will be necessary to ...

A $1.5 million gift to UC San Diego will help fund a research program into the biological and psychological effect of a powerful psychedelic in humans, it was announced Tuesday. N, ...

Algernon NeuroScience (AGN Neuro), a subsidiary of Algernon Pharmaceuticals Inc. AGNPF AGN AGW, has completed a feasibility study and has finalized its clinical trial design for a 40 patient phase 2 ...

As we venture further into this new era of psychedelic innovation and discovery, more folks are becoming aware of the potential benefits of substances like psilocybin, LSD, or ketamine. But what about ...

-- Expected to accelerate clinical development pathway of CYB004 for the potential treatment of anxiety disorders by nine months -- About the CYB004-E Study The CYB004-E study is an adaptive, ...

VLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradigm in interventional psychiatry VLS-01 ...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, ...

A $1.5 million gift to UC San Diego will help fund a research program into the biological and psychological effect of a powerful psychedelic in humans, it was announced Tuesday. N,N-dimethyltryptamine ...